Cambridge Healthtech Institute’s 2nd Annual

Targeting Autophagy
( 自噬的标靶化 )


Autophagy is regarded as the intracellular recycling machinery for degrading and reusing cytosolic materials. It acts as a node connecting many cellular events, therefore, targeting autophagy could eliminate the need to target multiple pathways. Autophagy has been shown to play a role in many diseases, such as cancer, autoimmune, CNS, metabolic and infectious disorders. However, targeting autophagy is complex because there are different types of autophagy and they all involve various cellular pathways that are not well understood. Many studies have shown that autophagy can also have a binary function, for instance, acting as a tumor suppressor or a tumor enhancer in cancer. Despite such complexities, it is promising to see many preclinical and clinical studies underway using already approved autophagy drugs and novel inhibitors. Cambridge Healthtech Institute’s symposium on Targeting Autophagy taps into the recent excitement in this field by bringing together a group of experts who are uncovering new mechanisms and inhibitors to help drug discovery. This symposium will be followed by a conference that focuses on targeting the ubiquitin-proteasome system and will draw on some of the synergies between these two areas of research.


Who should attend: SCIENTISTS and EXECUTIVES from Pharma, Biotech, Academia, Government, Contract Research Labs and Technology Providers involved in target ID & validation, discovery biology, cancer biology, immunology, discovery chemistry, biochemistry, molecular & cell biology, phenotypic screening, assay development, chemical biology, and other areas related to early drug discovery & development.


Coverage will include, but is not limited to:                                        

  • Understanding the cellular effects of targeting autophagy
  • Finding better tools and assays to simulate, probe and quantify the autophagy cascade
  • Developing in vitro assays and in vivo models to find autophagy targets for drug intervention
  • Novel probes and inhibitors targeting ULK1, VSP34, ATG4b, ATG7, Beclin-1, SNARE, mTOR and more
  • Emerging role of autophagy in oncology, CNS, autoimmune, metabolic and infectious diseases
  • Interplay between autophagy and immune responses
  • Functional interrelations between autophagy and the ubiquitin-proteasome system (UPS)
  • Development of autophagy inhibitors to be used as solo or combination therapies


* 活动内容有可能不事先告知作更动及调整。

Choose your language